Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Lisbon – page 23

638 clinical trials in Lisbon, Portugal across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Lisbon at a glance
638
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

638 trials in Lisbon

Open in trial search

Urinary tract infection

Not yet recruiting

MV140 for Women with Recurrent Uncomplicated Urinary Tract Infections

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Ascorbic Acid
  • Sponsor:Inmunotek S.L.

Pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:ADMILPARANT
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Mite allergy

Not yet recruiting

A study testing dust mite allergy extracts from Dermatophagoides pteronyssinus and Dermatophagoides farinae for patients with allergic rhinoconjunctivitis with or without controlled asthma

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:LETI Pharma S.L.U.

Acquired ATTR amyloidosis

Not yet recruiting

A Study of Acoramidis for Long-Term Safety in Patients with Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Acoramidis Hydrochloride
  • Sponsor:Eidos Therapeutics Inc.

Systemic lupus erythematosus+1

Not yet recruiting

Study of CC-97540 CD19-targeted CAR T cells in patients with systemic lupus erythematosus who did not respond to previous immunosuppressive treatment

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.

Non-small cell lung cancer

Not yet recruiting

Study on JDQ443 for First-Line Treatment in Patients with Advanced KRAS G12C-Mutated Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:1-{6-[(4M)-4-(5-Chloro-6-Methyl-1H -Indazol-4-Yl)-5-Methyl-3-(1-Methyl-1H -Indazol-5-Yl)-1H -Pyrazol-1-Yl]-2-Azaspiro[3.3]Heptan-2-Yl}Prop-2-En-1-One
  • Sponsor:Novartis Pharma AG

Non-small cell lung cancer

Not yet recruiting

Study to Compare Zongertinib with Standard Treatment for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Cystic fibrosis

Not yet recruiting

Study on the Effects of Dirocaftor, Posenacaftor, and Nesolicaftor for Adults with Cystic Fibrosis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Dirocaftor
  • Sponsor:Universitair Medisch Centrum Utrecht

Breast cancer

Not yet recruiting

Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Eli Lilly & Co.

Hepatitis alcoholic+1

Not yet recruiting

Study on the Safety and Effects of Resatorvid and Filgrastim for Patients with Severe Alcoholic Hepatitis and Acute-on-Chronic Liver Failure

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Filgrastim
  • Sponsor:Alpha Bioresearch S.L.

Macular oedema

Not yet recruiting

Study on the Effects of RO7200220 for Patients with Uveitic Macular Edema

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Humanised Igg2 Monoclonal Antibody Against Interleukin-6
  • Sponsor:F. Hoffmann-La Roche AG

Acute myeloid leukaemia

Not yet recruiting

Study on the Safety of Ivosidenib and Azacitidine for Adults with Newly Diagnosed IDH1m Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Servier Affaires Medicales

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Lisbon

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on head and neck cancer treatments and advanced lung cancer therapies, combining novel approaches with standard treatments.

  • Head & Neck Squamous Cell Carcinoma
  • Mantle Cell Lymphoma
  • Non-small Cell Lung Cancer

Studies evaluate targeted therapies and immunotherapy combinations to improve patient outcomes.

02 Autoimmune Conditions

Comprehensive research into various autoimmune disorders, with particular focus on psoriasis and systemic sclerosis treatments.

  • Psoriatic Arthritis
  • Sjögren's Syndrome
  • Plaque Psoriasis

Testing innovative biological therapies and novel treatment approaches.

03 Neurological Disorders

Studies examining treatments for Dravet Syndrome and Alzheimer's-related psychosis, focusing on improving patient quality of life.

  • Alzheimer's Disease Psychosis
  • Epilepsy Conditions

Investigating new therapeutic options for challenging neurological conditions.

04 Inflammatory Diseases

Research targeting Crohn's Disease and various inflammatory conditions, evaluating new treatment combinations.

  • Pyoderma Gangrenosum
  • Chronic Rhinosinusitis
  • Hidradenitis Suppurativa

Testing advanced therapies for chronic inflammatory conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.